^
    Back
    Association details:
    Biomarker:CLDN6 expression
    Cancer:Ovarian Cancer
    Drug:TORL-1-23 (Microtubule inhibitor, CLDN6-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    IGCS 2023
    Title:

    FIRST-IN-HUMAN PHASE 1 STUDY OF TORL-1-23, A NOVEL CLAUDIN 6 (CLDN6) TARGETED ANTIBODY DRUG CONJUGATE (ADC) IN PATIENTS WITH OVARIAN CANCER

    Published date:
    10/18/2023
    Excerpt:
    In participants with heavily-pretreated CLDN6-expressing ovarian cancer, the novel TORL-1-23 ADC shows a favorable safety/tolerability profile and encouraging antitumor activity.
    Trial ID:
    NCT05103683
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO 2023
    Title:

    756P - First-in-human phase I study of a novel claudin 6 (CLDN6) targeted antibody drug conjugate (ADC) TORL-1-23

    Published date:
    10/16/2023
    Excerpt:
    Partial responses (PR) were observed in 7/22 (32%) efficacy evaluable participants with CLDN6+ disease (6 ovarian, 1 testicular) across dose levels. 3/3 (100%) participants with CLDN6+ ovarian cancer responded at the 2.4 mg/kg dose level….In participants with heavily-pretreated CLDN6-expressing ovarian cancer, the novel TORL-1-23 ADC has a favorable safety/tolerability profile and encouraging antitumor activity in a phase 1 dose finding study.
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2023
    Title:

    Initial results of dose finding in a first-in-human phase 1 study of a novel Claudin 6 (CLDN6) targeted antibody drug conjugate (ADC) TORL-1-23 in patients with advanced solid tumors.

    Published date:
    05/25/2023
    Excerpt:
    TORL-1-23 has a favorable safety/tolerability profile and PK characteristics with preliminary antitumor activity in pts with heavily-pretreated CLDN6-expressing ovarian and testicular cancers.
    DOI:
    10.1200/JCO.2023.41.16_suppl.3082